BOC

The Body-on-a-Chip (BoC)

Coordinatore	INSPHERO AG    more  Organization address address: TECHNOPARKSTRASSE 1 city: ZURICH postcode: 8005 contact info Titolo: Dr. Nome: Jan Cognome: Lichtenberg Email: send email Telefono: 41445150499
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	1˙919˙000 €
EC contributo	1˙395˙000 €
Programma	FP7-ICT Specific Programme "Cooperation": Information and communication technologies
Code Call	FP7-ICT-2011-C
Funding Scheme	CP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-06-01   -   2015-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	INSPHERO AG  Organization address address: TECHNOPARKSTRASSE 1 city: ZURICH postcode: 8005 contact info Titolo: Dr. Nome: Jan Cognome: Lichtenberg Email: send email Telefono: 41445150499	CH (ZURICH)	coordinator	0.00
2	ASTRAZENECA UK LIMITED  Organization address address: STANHOPE GATE city: LONDON postcode: W1K 1LN contact info Titolo: Dr. Nome: Eric Cognome: Tang Email: send email Telefono: +44 1625515781	UK (LONDON)	participant	0.00
3	EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH  Organization address address: Raemistrasse city: ZUERICH postcode: 8092 contact info Titolo: Prof. Nome: Andreas Cognome: Hierlemann Email: send email Telefono: +41 61 387 3150	CH (ZUERICH)	participant	0.00
4	FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ E.V.  Organization address address: ARDEYSTRASSE city: DORTMUND postcode: 44139 contact info Titolo: Prof. Nome: Jan Cognome: Hengstler Email: send email Telefono: +49 231 1084 348 Fax: +49 231 1084 403	DE (DORTMUND)	participant	0.00
5	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt city: LEUVEN postcode: 3000 contact info Titolo: Ms. Nome: Sofie Cognome: Heroes Email: send email Telefono: +32 16 329979 Fax: +32 16 326515	BE (LEUVEN)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

High attrition and failures rates in pharmaceutical and biotechnological drug development require a paradigm change towards more physiological human cell-based assays at an early time point in the process. The central idea of this proposal is to develop a versatile and reconfigurable pharmaceutical screening technology platform that relies on organotypic three-dimensional spherical microtissues. This platform will accommodate different types of human microtissues (tumor, brain, liver, heart etc.) and feature microfluidic interconnection between these tissues, thus mimicking the physiological context and conditions in a human body. Dosage of components or candidate drugs to, e.g., liver tissue will lead to the generation of metabolic products in the respective tissue compartment. These products then can be routed via the microfluidics to, e.g., connective tissue to assess the efficacy of the candidate drug and related adverse toxicological effects on the target tissue and functionally related tissues. This way, functional connectivity in a real body can be mimicked at the desired level of complexity, and the effects of drugs can be comprehensively assessed.